0001484612-23-000002.txt : 20230104
0001484612-23-000002.hdr.sgml : 20230104
20230104171513
ACCESSION NUMBER: 0001484612-23-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230104
DATE AS OF CHANGE: 20230104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vazquez Martin
CENTRAL INDEX KEY: 0001823380
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39513
FILM NUMBER: 23507895
MAIL ADDRESS:
STREET 1: 3052 ORCHARD DR.
CITY: SAN JOSE
STATE: CA
ZIP: 95134
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outset Medical, Inc.
CENTRAL INDEX KEY: 0001484612
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 200514392
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 3052 ORCHARD DRIVE
CITY: SAN JOSE
STATE: CA
ZIP: 95134
BUSINESS PHONE: 669-231-8200
MAIL ADDRESS:
STREET 1: 3052 ORCHARD DRIVE
CITY: SAN JOSE
STATE: CA
ZIP: 95134
FORMER COMPANY:
FORMER CONFORMED NAME: Home Dialysis Plus, Ltd.
DATE OF NAME CHANGE: 20100219
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2023-01-03
0
0001484612
Outset Medical, Inc.
OM
0001823380
Vazquez Martin
3052 ORCHARD DRIVE
SAN JOSE
CA
95134
0
1
0
0
Chief Operating Officer
Common Stock
2023-01-03
4
M
0
5000
3.88
A
54290
D
Common Stock
2023-01-03
4
S
0
5000
26.1432
D
49290
D
Performance Options (right to buy)
3.88
2023-01-03
4
M
0
5000
0.0
D
2027-12-19
Common Stock
5000
73007
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2022.
The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $25.00 - $25.99 - 1,991 shares; $26.00 - $26.99 - 3,009 shares. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote.
In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.
By: John L Brottem For: Martin Vazquez
2023-01-04